<DOC>
	<DOC>NCT00678626</DOC>
	<brief_summary>This study will assess the effectiveness of CP- 751,871 when given in combination with docetaxel to women with the first occurrence of advanced breast cancer disease. The effectiveness will be measured by progression-free survival duration. Patients will be followed for 2 years from the date of randomization.</brief_summary>
	<brief_title>Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>histologically or cytologically confirmed diagnosis with evidence of either metastatic disease (Stage IV) of locally recurrent disease not amenable to curative resection or radiation therapy (Stage IIIB). Her2negative breast cancer or unknown Her2 status. at least 1 measurable lesion as defined by RECIST. ECOG status 01 adequate bone marrow, hepatic and renal function. left ventricular ejection fraction of greater than or equal to 50%. willingness to discontinue hormonal therapy. any previous chemotherapy for advanced disease. prior exposure to taxanes as (neo) adjuvant treatment less than 12 months prior to randomization. symptomatic brain metastases. prior antiIGF1R based investigational therapy. peripheral neuropathy greater than grade 2.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Key words: Docetaxel; breast cancer; breast diseases; breast neoplasms; antineoplastic agents; neoplasms;HER-2 negative; Stage IIIB or IV breast cancer.</keyword>
</DOC>